# Crinetics Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crinetics-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.crinetics.com
- Total disclosed funding: $105M
- Latest round: Series B (Feb 9, 2018)
- Investors on record: 6

## About

Founded in 2008 and based in California, US, Crinetics Pharmaceuticals Inc. is a pharmaceutical company that manufactures and distributes medical drugs for endocrine diseases and cancer. These drugs include an oral selective nonpeptide somatostatin receptor type 2 biased agonist, a treatment for acromegaly; an oral selective nonpeptide somatostatin type 5 receptor agonist, a treatment for congenital hyperinsulinism; and an oral, selective nonpeptide sst2 biased agonist, a treatment for neuroendocrine tumors.

## Funding rounds

- Series B, Feb 9, 2018, $65M — OrbiMed Advisors, Versant Ventures, 5AM Ventures, Vivo Capital, RA Capital Management, Perceptive Advisors
- Series A, Nov 2, 2015, $40M — Versant Ventures, 5AM Ventures, Vivo Capital

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B